The Biomarker: Melanoma

Sanjiv S. Agarwala, MD
Video Categories: The Biomarker

PMO is pleased to offer the department “The Biomarker” to discuss the identification of biomarkers in patients with cancer and the prognostic/predictive impact and clinical decision-making implications of that marker. This month, we focus on KIT mutations in melanoma patients. Dr Sanjiv Agarwala provides his insights on this provocative topic.
March 31, 2015

Improving Myeloma Outcomes

Dr. Ajai Chari discusses the ultimate goal of improving therapy for myeloma patients. He mentions the COMPASS study, which is working to collect a database of clinical and scientific information on 1000 patients. In the interim, there are some clues, such as an understanding of certain high-molecular-risk patients and some [ Read More ]

March 31, 2015

Precision Medicine for CLL

Dr. Jennifer R. Brown deliberates on the state of personalized medicine in relation to CLL. She explains that the targeted drugs currently used for CLL actually work for most patients, rather than just a subgroup. Also, CLL therapies are now generally in pill form and well tolerated with few side [ Read More ]